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Introduction
Epidermolysis bullosa (EB) encompasses a group of
heterogeneous diseases of the skin and mucous mem-
branes, which share the common feature of the for-
mation of blisters and erosions in response to minor
mechanical trauma. Most cases of EB are inherited.1,2
A comprehensive classification based on clinical pres-
entation, genetic pattern of inheritance and electron
microscopic features was proposed in 1991 by the
Subcommittee of the National EB Registry.3 EB is
classified into 3 groups by the level at which the sepa-
ration occurs: EB simplex (EBS; intraepidermal skin
separation); junctional EB (JEB; skin separation in
lamina lucida); and dystrophic EB (DEB; sublamina
densa separation). EB is easily misdiagnosed as infec-
tious bullous disease. The management of the former
is primarily supportive and preventive, and that of the
latter is with antibiotics. It is certainly important to
distinguish between EB and infectious bullous diseases
because skin biopsies are required for appropriate diag-
nosis and classification of EB.2
The incidence of EB estimated by a National EB
Registry report is 50 EB cases occurring per 1 million
live births; of these cases, approximately 92% will be
EBS, 5% DEB, 1% JEB, and 2% unclassified.1 We
describe a patient with JEB (which has an incidence
of 0.5 per million1) who was managed initially with
AQUACEL® Ag dressing.
Case Report
This was a male neonate of 36 weeks’ gestation, birth
weight of 2,846 g, Apgar scores of 8 and 9 at 1 and 
5 minutes, respectively, and normal spontaneous deliv-
ery. The mother had developed urinary tract infection
11 days before delivery, and she had been given cefa-
zolin for 1 week. There was no consanguinity or family
history of any bullous disease. The patient was noted
at birth to have blisters with erosions on the face, scro-
tum and four extremities, especially at the wrists and
ankles (Figure 1).
He was then referred to a tertiary teaching hospital
where physical examination on admission revealed a
tympanic temperature of 37°C, pulse of 140 beats/
minute, respiratory rate of 40/minute, and blood pres-
sure of 65/41 mmHg. Breath sounds were clear, and
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heart examination was normal. In addition to the skin
lesions, 1 blister was found in the oral cavity. Antibiotics
(oxacillin and gentamicin) were initially prescribed on
the presumption that the bullae were secondary to
bacterial infection. Laboratory investigations showed:
white blood cell count, 4,200/mm3 (with neutrophils
22.6%, lymphocytes 69.5%, monocytes 3.2%); hemo-
globin, 16.7g/dL; platelets, 313,000/mm3; C-reactive
protein, 0.15 mg/dL. Antibiotics were discontinued
on the 2nd day of admission due to no obvious focus
of bacterial infection. Wound culture and blood cul-
ture were subsequently found to be negative.
Over the subsequent few days, new blisters devel-
oped on the trunk, buttocks and thighs, especially 
at friction points. Areas of re-epithelialization and
remnants of blister roofs were seen at the periphery of
fresh erosions. The whole skin was very fragile, and han-
dling the baby caused new blisters. The wounds were
covered with AQUACEL® Ag dressing (ConvaTec, A
Bristol-Myers Squibb Company, Princeton, NJ, USA)
followed by gauze padding and elastic bandage.
Skin biopsy was performed when he was 6 days
old. Histopathology revealed subepidermal blistering
without inflammatory cells. The roof of the blister
consisted of full-thickness epidermis. The picture was
compatible with EB (Figure 2A). Direct immuno-
fluorescence of lesional skin was negative for IgG,
IgA, IgM and C3. Immunofluorescence mapping with
fluorescing antisera against collagen type IV (local-
ized in the lamina densa) showed a positive linear
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Figure 1. A neonate with junctional epidermolysis bullosa has blisters with erosions on the face, scrotum and 4 extremities.
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Figure 2. (A) Histopathology shows subepidermal blistering without inflammatory cells. The roof of the blister consists of full-thickness
epidermis. The picture is compatible with epidermolysis bullosa (original magnification, 400×). (B) Immunofluorescence mapping with
fluorescing antisera against type IV collagen (localized on the lamina densa) shows a positive linear immunofluorescence (arrow) at the base
of the blister. This allocation of collagen type IV in the blister indicates a junctional cleavage. E = epidermis; B = blister; LD = lamina densa.
immunofluorescence at the base of the blister (Figure
2B). In turn, collagen type IV was present in the lamina
densa. This allocation of collagen type IV in the blis-
ter indicated a junctional cleavage.4,5
Electron microscopy demonstrated that the cleavage
plane of the blister was in the lamina lucida. The lam-
ina densa was on the floor of the blister. There were
no cytoplasmic remnants of basal keratinocytes above
the lamina densa. In addition, well-preserved anchor-
ing fibrils (collagen type VII) in the dermis were pres-
ent, but no hemidesmosomes were noted at the basal
lamina (Figure 3). JEB was the diagnosis.
The patient was discharged after hospitalization
for 28 days. The wounds were covered with AQUA-
CEL® Ag dressing after discharge home. He was reg-
ularly followed-up at our outpatient department. At
the age of 3 months, his body weight was 5.6 kg, and
his general condition was much improved. The previ-
ous blisters with erosions were healing gradually, and
the development of new blisters was gradually being
reduced with the use of AQUACEL® Ag dressing.
Discussion
A neonate presenting with blisters opens a broad spec-
trum of differential diagnoses which include infectious
diseases such as bullous impetigo, staphylococcal
scalded skin syndrome, or toxic epidermal necrolysis,
and immunologic diseases such as pemphigus or bul-
lous pemphigoid, and hereditary diseases such as EB.
Differential diagnosis is based on clinical examination,
histopathology, direct immunofluorescence and bac-
terial culture. The initial presentation of this case
included a few blisters with erosions on the skin after
birth, a picture that is difficult to differentiate from
staphylococcal scalded skin syndrome. However, there
was no obvious focus of infection. Subsequent labora-
tory studies including blood and wound cultures were
negative.
EB can be differentiated from immunologic bullous
dermatoses through histologic and immunofluorescent
methods. In EB, the histologic picture is subepider-
mal bulla without inflammatory cells, while the direct
immunofluorescence of both lesional and non-lesional
skin is negative for IgA, IgG, IgM and C3.5 Histo-
pathology is generally not very helpful in delineating
a specific subtype of EB, since all subtypes appear as
subepidermal splits on light microscopy.5 Ultrastruc-
turally, EBS shows an intraepidermal separation at the
level of basal cells; JEB and DEB show a subepidermal
split through the lamina lucida, or beneath the lamina
densa, respectively.6 The level of tissue separation can be
rapidly and reliably detected using immunofluorescence
mapping.7 Based on immunofluorescence staining, this
method relates the level of cleavage to specific markers
for structural proteins, which are strongly expressed in
both normal skin and skin from EB patients. In JEB,
anti-BP180 (anti-collagen type XVII) antibody will be
located on the roof of the blister, whereas collagen type
IV antibodies stain the floor.4,5 In this patient, immuno-
fluorescence mapping with antisera against collagen
type IV showed a positive linear immunofluorescence
at the base of the blister. This allocation of collagen
type IV in the blister indicated a junctional cleavage.
There are more than 25 subtypes of EB, and they
often become manifest at birth or during the 1st year
of life.1 The more severe the involvement, the earlier
the blisters will occur, usually from mild trauma such
as that encountered when a baby crawls or lifts objects
or during teething.8 Each type of EB has several variants
based on inheritance, prognosis and clinical features.
EBS is usually associated with little or no extracuta-
neous involvement, while the more severe junctional
and dystrophic forms of EB may produce significant
multiorgan involvement.9 EBS, mostly an autosomal
dominant disorder, comprises 92% of EB. There is an
intraepidermal cleavage at the lower portion, owing to
cytolytic alterations of basal keratinocytes with defects
in cytokeratins 5 (KRT5 gene) and 14 (KRT14 gene).10
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Figure 3. Electron microscopy shows that the cleavage plane of
the blister is in the lamina lucida. The lamina densa, measuring
about 30–46 nm, is on the floor of the blister. There are no cyto-
plasmic remnants of basal keratinocytes above the lamina densa.
Well-preserved anchoring fibrils in the dermis are present, but no
hemidesmosomes are noted at the lamina densa. Junctional epi-
dermolysis bullosa was diagnosed. LL = lamina lucida; B = blister;
LD = lamina densa; AF = anchoring fibrils; D = dermis.
JEB is an autosomal recessive disorder characterized
by cleavage at the lamina lucida. JEB mutations have
been described in the 3 genes (LAMA3, LAMB3,
LAMC2) that encode the anchoring filament protein,
laminin 5, and the 2 transmembrane components of
the hemidesmosome, collagen type XVII and integrin
α6β4.10 DEB includes autosomal recessive and domi-
nant forms. The mechanism of the disorder is a muta-
tion in the gene encoding collagen type VII, leading to
defective anchoring fibrils and causing sublamina densa
separation.11,12 Skin biopsies are required for appro-
priate diagnosis and classification in affected patients.2
The management of EB is primarily preventive and
supportive, consisting of prevention of trauma, careful
wound care, nutritional support and infection control.
Surgical procedures are indicated when deformities
are caused by the blistering and scarring.13 Steroid
therapy is controversial for EB; since EB are genetic dis-
orders, no drug is capable of correcting the molecular
defect.14 Gene therapy is, potentially, a future therapy.
Recently, researchers have reported sustainable genetic
correction of JEB patient skin tissue with laminin 5
gene delivery.15 Clinical physicians should provide
genetic counseling for families at risk for EB.
The prognosis of EB depends on the severity of
the illness. Primary subtypes of JEB include a lethal
subtype (usually resulting in death in infancy) termed
Herlitz or JEB letalis, a nonlethal subtype (with appar-
ent scalp, nail and tooth abnormalities) termed JEB
mitis, and a generalized benign type termed generalized
atrophic benign EB (GABEB).9 These varieties are dis-
tinguished clinically, although molecular studies may
be useful. Our patient likely has the GABEB subtype
that clinically improves with age. He has the potential
to father children and has a normal life expectancy.9
References
1. Fine JD, Bauer EA, Gedde-Dahl T. Inherited epidermolysis
bullosa: definition and historical overview. In: Fine JD, Bauer EA,
McGuire J, eds. Epidermolysis Bullosa: Clinical, Epidemiologic,
and Laboratory Advances and the Findings of the National
Epidermolysis Bullosa Registry. Baltimore: Johns Hopkins
University Press, 1999:1–19.
2. Fine JD, Eady RA, Bauer EA. Revised classification system 
for inherited epidermolysis bullosa: report of the Second
International Consensus Meeting on Diagnosis and Classification
of Epidermolysis Bullosa. J Am Acad Dermatol 2000;42:
1051–66.
3. Fine JD, Bauer EA, Briggaman RA. Revised clinical and labo-
ratory criteria for subtypes of inherited epidermolysis bullosa:
a consensus report by the Subcommittee on Diagnosis and
Classification of the National Epidermolysis Bullosa Registry. 
J Am Acad Dermatol 1991;24:119–35.
4. Hintner H, Stingl G, Schuler G, Fritsch P, Stanley J, Katz S,
Wolff K. Immunofluorescence mapping of antigenic determi-
nants within the dermal–epidermal junction in the mechano-
bullous diseases. J Invest Dermatol 1981;76:113–8.
5. Bergman R. Immunohistopathologic diagnosis of epidermolysis
bullosa. Am J Dermatopathol 1999;21:185–92.
6. McAllister JC, Marinkovich MP. Advances in inherited epider-
molysis bullosa. Adv Dermatol 2005;21:303–34.
7. Bruckner-Tuderman L. Hereditary skin diseases of anchoring
fibrils. J Dermatol Sci 1999;20:122–33.
8. Horn HM, Priestley GC, Eady RA, Tidman MJ. The preva-
lence of epidermolysis bullosa in Scotland. Br J Dermatol 1997;
136:560–4.
9. Lin AN, Carter DM. Epidermolysis bullosa. Annu Rev Med
1993;44:189–99.
10. Fine JD, McGrath J, Eady R. Inherited epidermolysis bullosa
comes into the new millennium: a revised classification system
based on current knowledge of pathogenic mechanisms and
the clinical, laboratory, and epidemiologic findings of large,
well-defined patient cohorts. J Am Acad Dermatol 2000;
43:135–7.
11. Vaccaro M, Moretti G, Guarneri F, Cannavo S, Magaudda L.
“Sporadic” dystrophic epidermolysis bullosa: a new dominant
or mitis recessive mutation? Eur J Dermatol 2000;10:436–8.
12. Hashimoto I, Kon A, Tamai K, Uitto J. Diagnostic dilemma 
of “sporadic” cases of dystrophic epidermolysis bullosa: a new
dominant or mitis recessive mutation? Exp Dermatol 1999;
8:140–2.
13. Marinkovich MP. Update on inherited bullous dermatoses.
Dermatol Clin 1999;17:473–85.
14. Marinkovich MP, Pai S. Epidermolysis bullosa: new and
emerging trends. Am J Clin Dermatol 2002;3:371–80.
15. Ortiz-Urda S, Lin Q, Yant SR, Keene D, Kay MA, Khavari PA.
Sustainable correction of junctional epidermolysis bullosa via
transposon-mediated nonviral gene transfer. Gene Therapy 2003;
10:1099–104.
J Chin Med Assoc • October 2006 • Vol 69 • No 10506
C.H. Kao, et al
